Somewhat Favorable Press Coverage Somewhat Unlikely to Affect ContraFect (CFRX) Stock Price

Headlines about ContraFect (NASDAQ:CFRX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ContraFect earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.26777450871 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

ContraFect (CFRX) traded up $0.04 during midday trading on Thursday, hitting $1.07. 15,242 shares of the stock were exchanged, compared to its average volume of 146,214. ContraFect has a twelve month low of $0.80 and a twelve month high of $2.50. The firm has a market capitalization of $75.87, a PE ratio of -5.63 and a beta of -0.85.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect ContraFect (CFRX) Stock Price” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://sportsperspectives.com/2018/01/04/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-contrafect-cfrx-stock-price.html.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Insider Buying and Selling by Quarter for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply